scholarly journals C-reactive protein levels in the perioperative period as a predictive marker of endoscopic recurrence after ileo-colonic resection for Crohn’s disease

2016 ◽  
Vol 2 (1) ◽  
Author(s):  
E Iaculli ◽  
M Agostini ◽  
L Biancone ◽  
C Fiorani ◽  
A Di Vizia ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Predictive Marker ◽  
Perioperative Period ◽  
Colonic Resection ◽  
C Reactive Protein ◽  
Protein Levels ◽  
Reactive Protein ◽  
Endoscopic Recurrence

PTH-052 C-reactive protein levels in the perioperative period as a predictive marker of endoscopical recurrence

Gut ◽  
2015 ◽  
Vol 64 (Suppl 1) ◽  
pp. A428.2-A428
Author(s):  
E Iaculli ◽  
GS Sica ◽  
L Biancone ◽  
G Tema ◽  
G Maggi ◽  
...  
Keyword(s):  
Predictive Marker ◽  
Perioperative Period ◽  
C Reactive Protein ◽  
Protein Levels ◽  
Reactive Protein

scholarly journals Postoperative Ratio of C-Reactive Protein to Albumin as a Predictive Marker in Patients with Crohn’s Disease Undergoing Bowel Resection

2021 ◽  
Vol 2021 ◽  
pp. 1-8
Author(s):  
Hangfen Zhao ◽  
Huaying Liu ◽  
Weilin Qi ◽  
Wei Liu ◽  
Lingna Ye ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Postoperative Complications ◽  
Crohn's Disease ◽  
Surgical Site Infections ◽  
Predictive Marker ◽  
Roc Curves ◽  
Youden Index ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Significant Independent Risk Factor

Background. The ratio of C-reactive protein (CRP) to albumin (CAR) has a significant correlation with postoperative complications and acts as a predictor in patients with pancreatic cancer and colorectal cancer. However, whether the CAR can be used to predict complications in Crohn’s disease (CD) patients after surgery has not yet been reported. Methods. A total of 534 CD patients undergoing surgery between 2016 and 2020 were enrolled. The risk factors of postoperative complications were assessed by univariate and multivariate analyses. The cutoff values and the accuracy of diagnosis for the CAR and postoperative CRP levels were examined with receiver operating characteristic (ROC) curves. Results. The rate of postoperative complications was 32.2%. The postoperative CAR (OR 13.200; 95% CI 6.501-26.803; P < 0.001 ) was a significant independent risk factor for complications. Compared with the CRP level on postoperative day 3, the CAR more accurately indicated postoperative complications in CD patients (AUC: 0.699 vs. 0.771; Youden index: 0.361 vs. 0.599). ROC curves showed that the cutoff value for the CAR was 3.25. Patients with a CAR ≥ 3.25 had more complications ( P < 0.001 ), a longer postoperative stay ( 15.5 ± 0.6  d vs. 9.0 ± 0.2  d, P < 0.001 ), and more surgical site infections (48.2% vs. 5.7%, P < 0.001 ) than those with a CAR < 3.25 . Conclusions. Compared to the CRP level, the CAR can more accurately predict postoperative complications and can act as a predictive marker in CD patients after surgery.

scholarly journals Adalimumab Treatment in Biologically Naïve Crohn’s Disease: Relationship with Ectopic MUC5AC Expression and Endoscopic Improvement

2014 ◽  
Vol 2014 ◽  
pp. 1-8 ◽  
Author(s):  
Tsutomu Mizoshita ◽  
Satoshi Tanida ◽  
Hironobu Tsukamoto ◽  
Keiji Ozeki ◽  
Takahito Katano ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Activity Index ◽  
Drug Efficacy ◽  
Predictive Marker ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Before And After ◽  
Adalimumab Treatment ◽  
Positive Groups

Background. Adalimumab (ADA) is effective for patients with Crohn’s disease (CD). However, there have been few reports on ADA therapy with respect to its relationship with pathologic findings and drug efficacy in biologically naïve CD cases.Methods. Fifteen patients with active biologically naïve CD were treated with ADA. We examined them clinically and pathologically with ectopic MUC5AC expression in the lesions before and after 12 and 52 weeks of ADA therapy, retrospectively.Results. Both mean CD activity index scores and serum C-reactive protein values were significantly lower after ADA therapy (P<0.001). In the MUC5AC negative group, all cases exhibited clinical remission (CR) and endoscopic improvement at 52 weeks. In MUC5AC positive groups, loss of MUC5AC expression was detected in cases having CR and endoscopic improvement at 52 weeks, while remnant ectopic MUC5AC expression was observed in those exhibiting no endoscopic improvement and flare up after 52 weeks.Conclusions. ADA leads to CR and endoscopic improvement in biologically naïve CD cases. In addition, ectopic MUC5AC expression may be a predictive marker of flare up and endoscopic improvement in the intestines of CD patients.

Sign in / Sign up

Export Citation Format

Share Document